In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris.

导出 OA

翻译打印收藏纠错

第一作者： Jeffrey M,Rybak

作者： Jeffrey M,Rybak ; Katherine S,Barker ; José F,Muñoz ; Josie E,Parker ; Suhail,Ahmad ; Eiman,Mokaddas ; Aneesa,Abdullah ; Rehab S,Elhagracy ; Steve L,Kelly ; Christina A,Cuomo ; P David,Rogers

关键词 Amphotericin B Candida auris ERG6 In?vivo evolution Resistance

主题词两性霉素B(Amphotericin B);抗真菌药(Antifungal Agents);人类(Humans);微生物敏感性试验(Microbial Sensitivity Tests);甾醇类(Sterols)

DOI 10.1016/j.cmi.2021.11.024

PMID 34915074

发布时间 2024-09-04

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical microbiology and infection

2022年28卷6期

838-843页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris.

Clinical microbiology and infection

相似文献

Clinical microbiology and infection

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in Candida auris.

Clinical microbiology and infection

相似文献

Clinical microbiology and infection

相关期刊

检索历史清除